Current guidelines for many critical illnesses recommend targeting a MAP of 65 mm Hg, with consideration of higher MAPs in older patients with chronic HTN. Recent literature, however, suggests increased mortality in older patients who are exposed to larger quantities of vasopressor medications. In this podcast, we do a deep dive into the recently published 65 Trial, which sought to evaluate the effect of permissive hypotension in older patients with vasodilatory hypotension.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
The World’s population is aging. By 2030, 20 percent of the US population will be over the age of 65 years. Older patients have...
A plethora of great articles pertaining to the care of critically ill patients were published in 2018. In this podcast, we review some of...
Up to one-third of patients with status epilepticus will not respond to benzodiazepines. Unfortunately, treatment of benzodiazepine-refractory status epilepticus is not well studied. The...
